Epithelial eotaxin-2 and eotaxin-3 expression: Relation to asthma severity, luminal eosinophilia and age at onset

Thorax

Volumn 67, Issue 12, 2012, Pages 1061-1066

  Coleman, John M ^a   Naik, Chetan ^a   Holguin, Fernando ^a   Ray, Anuradha ^a   Ray, Prabir ^a   Trudeau, John B ^a   Wenzel, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CORTICOSTEROID; DEXAMETHASONE; EOTAXIN 2; EOTAXIN 3; MESSENGER RNA;

ADULT; ARTICLE; ASTHMA; CELL MIGRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC INFLAMMATION; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY EPITHELIUM; SPUTUM;

EID: 84869239715     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201634     Document Type: Article

References (33)

1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.
2. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8. (Pubitemid 29442043)
3. Haldar PBC, Hargadon B, Gupat S, et al. Mepolizumab (anti-IL 5) and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
4. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-8. (Pubitemid 38096168)
5. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164:744-8. (Pubitemid 32881907)
6. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007;119:1303-10; quiz 1311-1302.
7. Humbert M, Corrigan CJ, Kimmitt P, et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997;156:704-8. (Pubitemid 27396404)
8. Nair P, Pizzichini M, Kjarsgaard MIM, et al. Mepolizumab in prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
9. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32.
10. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36. (Pubitemid 38056318)
11. Stellato C, Matsukura S, Fal A, et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999;163:5624-32.
12. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001;24:755-61. (Pubitemid 32550599)
13. Zimmermann N, Hershey GK, Foster PS, et al. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003;111:227-42; quiz 243.
14. Ravensberg AJ, Ricciardolo FL, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol 2005;115:779-85. (Pubitemid 40460853)
15. Komiya A, Nagase H, Yamada H, et al. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol 2003;225:91-100. (Pubitemid 38091553)
16. Lilly CM, Nakamura H, Belostotsky OI, et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-75. (Pubitemid 32578774)
17. Berkman N, Ohnona S, Chung FK, et al. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001;24:682-7. (Pubitemid 32550589)
18. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13. (Pubitemid 46210080)
19. Trudeau J, Hu H, Chibana K, et al. Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J Allergy Clin Immunol 2006;117:1446-54. (Pubitemid 43795756)
20. Moore WC, Evans MD, Bleecker ER, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol 2011;128:328-336.e3.
21. Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147:1126-31. (Pubitemid 23149867)
22. Zhao J, O'Donnell VB, Balzar S, et al. 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci USA 2011;108:14246-51.
23. Gould W. Quantile regression with bootstrapped standard errors. Stata Tech Bull 1993;2:19-21.
24. Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:299-309.
25. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.
26. Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767-73. (Pubitemid 27163829)
27. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507-16. (Pubitemid 28018050)
28. van Wetering S, Zuyderduyn S, Ninaber DK, et al. Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. Mol Immunol 2007;44:803-11. (Pubitemid 44415012)
29. Pang L, Nie M, Corbett L, et al. Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities. J Immunol 2006;176:3788-95. (Pubitemid 43364027)
30. Banwell ME, Tolley NS, Williams TJ, et al. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. Cytokine 2002;17:317-23.
31. Scheicher ME, Teixeira MM, Cunha FQ, et al. Eotaxin-2 in sputum cell culture to evaluate asthma inflammation. Eur Respir J 2007;29:489-95. (Pubitemid 46372095)
32. Pope SM, Fulkerson PC, Blanchard C, et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 2005;280:13952-61. (Pubitemid 40517296)
33. Watanabe K, Jose PJ, Rankin SM. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol 2002;168:1911-18. (Pubitemid 34135793)